114
Participants
Start Date
July 31, 2003
Primary Completion Date
August 31, 2005
Study Completion Date
August 31, 2005
Prasterone (GL701)
"There were 4 arms to the study:~During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study."
Albert Einstein Medical School, The Bronx
North Shore University Hospital, Division of Rheumatology, Manhasset
SUNY Downstate Medical Center, Brooklyn
Immunology/Rheumatology Instituto Nacional de Ciencias Medicas y Nutricion, S.Z., Mexico City
University of Pittsburgh, Pittsburgh
Altoona Center for Clinical Research, Duncansville
Johns Hopkins University, Baltimore
Sentara Medical Group DBA, Virginia Beach
Center for Rheumatology, Immunology and Arthritis, Fort Lauderdale
Tampa Medical Group, P.A., Tampa
Northwestern University, Chicago
Washington University School of Medicine, St Louis
St. John's Medical Research Group, Springfield
Oklahoma Center for Arthritis Therapy, Tulsa
University of Arizona, Tucson
Wallace Rheumatic Study Center, Los Angeles
Lifestyles Health Science Center, Rancho Mirage
East Bay Rheumatology Group, San Leandro
Oregon Health & Science University, Portland
Seattle Rheumatology Associates, Seattle
University of California San Diego, San Diego
Rheumatology Associates of Central Florida, Orlando
Lead Sponsor
Genelabs Technologies
INDUSTRY